Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 6/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711889 | 0.90 | USP2 (0.49) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL17624331 | 0.89 | KDM4E (0.56) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL19658449 | 0.88 | CYP1A2 (0.46) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL23763347 | 0.88 | CYP1A2 (0.52) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL15632465 | 0.87 | CYP1A2 (0.62) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL19504703 | 0.83 | OPRM1 (0.47) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL27007062 | 0.83 | USP2 (0.54) | USP2CYP1A2ALDH1A1CYP2D6HSD17B10 | |
| SCHEMBL26783934 | 0.82 | USP2 (0.60) | USP2CYP1A2TDP1ALDH1A1CYP2D6 | |
| SCHEMBL31008711 | 0.82 | USP2 (0.53) | USP2CYP1A2ALDH1A1CYP2D6HSD17B10 | |
| SCHEMBL18390599 | 0.81 | CYP1A2 (0.54) | USP2CYP1A2TDP1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096995-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(6-MEMBERED HETEROCYCLOALKYL)-2-METHYLPYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE ANALOGUES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | CTSS, CTSK, CTSZ | USP2 4677/4885CYP1A2 2961/4885TDP1 2847/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | USP2 130/4885CYP1A2 4026/4885TDP1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.